|Bid||0.00 x 0|
|Ask||0.00 x 0|
|Day's Range||80.49 - 80.71|
|52 Week Range||50.08 - 91.87|
|Beta (5Y Monthly)||0.15|
|PE Ratio (TTM)||17.55|
|Forward Dividend & Yield||0.95 (1.19%)|
|Ex-Dividend Date||Mar 29, 2021|
|1y Target Est||97.00|
Subscribe to Yahoo Finance Plus to view Fair Value for FUJIYLearn more
FUJIFILM (FUJIY) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
In the not-too-distant future, you may be able to walk into a doctor’s office, get tested for SARS-CoV-2, and walk out with pills or a prescription if you end up testing positive for the virus. “Finally, we have another potential tool,” Dr. Anthony Fauci, director of the National Institute of Allergy and Infectious Diseases and chief medical adviser to President Joe Biden, said Oct. 6 at a White House briefing, “a promising new oral drug that people could take at home soon after COVID-19 to reduce the risk of severe outcomes.” The drug is molnupiravir, which Merck & Co. Inc. (MRK) and Ridgeback Therapeutics say cuts the risk of hospitalization and death by 50%.
Japanese shares fell on Monday as concerns of slow economic growth due to the highly contagious Delta variant of COVID-19 weighed on investor sentiment, while market heavyweights Toyota Motor and Sony Group dropped due to a stronger yen. "And the worse-than-expected outcome of the University of Michigan's consumer survey indicated an impact of the Delta variant in the U.S. and that weakened the dollar." The survey released last week showed consumer sentiment slid to the lowest level since 2011 amid an acceleration in COVID-19 infections caused by the Delta variant.